Global Infectious Disease Diagnostics Market
Infectious disease diagnostics are the procedures for identification and characterization of the causative agent of an infectious disease with the aid of diagnostic tools. These diagnostics provide crucial information for making right medical decisions. Infectious diseases caused by various micro-organisms such as viruses, bacteria, fungi, and parasites. Infectious diseases transmitted from person to person through either indirect or direct contact. Infectious diseases such as bacterial infections, fungal infections, and viral infections such as respiratory diseases, HPV, HIV, measles, malaria, dengue, cholera, and hepatitis B and C are gradually spreading worldwide. Infectious disease diagnostics can be based solely on clinical presentation or more rigorous diagnostic tests, such as microscopy, biochemical screens, culturing of an infectious agent, and molecular methods.
The key drivers for the growth of the infectious disease diagnostics market increase in the prevalence of dengue, malaria, and HIV, rise in the preference for rapid diagnosis, increase in government funding for the establishment of diagnostic centers, and technological advancements in diagnostic procedures expected to fuel the infectious disease diagnostics market. Furthermore, increase in the R&D activities for newer assays, changing demographics around the globe, and advances in healthcare infrastructure are expected to boost the infectious disease diagnostics market. However, high cost for the diagnostic procedures, lack of awareness about the novel diagnostic procedures, dearth of skilled professionals to perform diagnostic tests, and lack of reimbursement policies for several diagnostic test might hamper the infectious disease diagnostics market growth over the forecast period.
The infectious disease diagnostics market has been segmented on the basis of test type, technique type, product type, infection type, and the end-user
Based on the test type, infectious disease diagnostics market has been segmented into following:
- Imaging Test
- Magnetic Resonance Imaging (MRI)
- Computed tomography (C.T)
- Laboratory Tests
- Blood Tests
- Urine Tests
- Stool Tests
- Spinal Tap
- Throat Swabs
Based on the product type, infectious disease diagnostics market has been segmented into following:
- Assay Kits and Consumables
Based on the infection type, infectious disease diagnostics market has been segmented into following:
- Sexually Transmitted Infectious Diseases
Based on the end-user, the infectious disease diagnostics market has been segmented into following:
- Diagnostic laboratories
- Home Healthcare
- Ambulatory Clinics
Geographically, the global infectious disease diagnostics market is in the flourishing stage, with the development of novel technologies by various players in the market. Increasing prevalence of the deadly infectious disease will drive the growth of the global infectious disease diagnostics market over the forecast period. For instance, according to World Health Organisation, global health observatory (GHO) data, in 2013, approximately 34-38 million people suffered from HIV infection worldwide. Innovation of technologically advanced devices with quick results, ease of usage, accuracy, and low-cost are expected to boost global infectious disease diagnostics market. For instance, in 2013, Abbott Molecular introduced a new range of real-time assays for hepatitis B virus, and hepatitis C virus infections on its m2000 platform. The majority of companies are making efforts to develop and commercialize cost-effective tools for the infectious disease diagnostics. Nowadays, the gold standard tests available for sexually transmitted disease and bacterial infection diagnosis, and these tests are expected to replace by molecular techniques in future.
Geographically, global infectious disease diagnostics market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global infectious disease diagnostics market followed by Europe and Asia-Pacific. The largest share of North-America region is due to increase in the prevalence of infectious diseases especially in U.S. According to UNAIDS, in 2012, about 1.3 Mn patients were diagnosed with HIV in the U.S. These statistics are likely to increase over the coming years, if suitable treatment options are not provided in time. The European region is expected to emerge as significant market owing to improved healthcare infrastructure, and increase in prevalence of bacterial and viral diseases (according to WHO European Region, at the end of 2015, about 13.3 Mn people live with chronic hepatitis B, an estimated 15 Mn people with hepatitis C, and more than 2 Mn people with HIV), which are expected to fuel the growth of the infectious disease diagnostics market in European region. Moreover, Asia-Pacific is a key region for the growth of global infectious disease diagnostics during the forecast period, due to the high prevalence of infectious diseases, and increasing in healthcare expenditure. Moreover, due to increase in incidence and prevalence of infectious diseases such as bacterial infections and sexually transmitted diseases and rise in population expected to drive significant growth of the infectious disease diagnostics market in Asia-Pacific region.
Some of the players in global infectious disease diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Thermo Fischer Scientific (U.S.), Abbott Laboratories (U.S.), Bio-Rad Laboratories Inc. (U.S.), Becton, Dickinson & Company (U.S.), and DiaSorin S.p.A. (Italy) to name a few.
- In 2016, Abbott unveiled Alinity, its unified family of innovative next-generation diagnostics system across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening, and molecular diagnostics
- In 2015, Bio-Rad FDA has approved Bio-Rad’s BioPlex 2200 human immunodeficiency virus (HIV) Antigen-Antibody assay, used for detection of HIV antibodies and HIV antigens
- In 2014, DiaSorin launched the new molecular diagnostic test for the detection of Toxoplasmosis
- The report provides granular level information about the market size, regional market share and forecast from 2017-2024
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario